ロード中...
SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study
Mantle cell lymphoma (MCL) is an aggressive B cell lymphoma, where survival has been remarkably improved by use of protocols including high dose cytarabine, rituximab and autologous stem cell transplantation, such as the Nordic MCL2/3 protocols. In 2008, a MCL international prognostic index (MIPI) w...
保存先:
| 出版年: | Br J Haematol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BlackWell Publishing Ltd
2014
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4282019/ https://ncbi.nlm.nih.gov/pubmed/24684350 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.12854 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|